Astrocytoma-associated antigens - IL13Rα2, Fra-1, and EphA2 as potential markers to monitor the status of tumour-derived cell cultures in vitro

详细信息    查看全文

• 作者：Monika Witusik-Perkowska ; Magdalena Zakrzewska…
• 关键词：IL13Rα2 ; Fra ; 1 ; EphA2 ; Astrocytomas ; Cell culture
• 刊名：Cancer Cell International
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：14
• 期：1
• 全文大小：2,504 KB
• 参考文献：1. Inagaki, A, Soeda, A, Oka, N, Kitajima, H, Nakagawa, J, Motohashi, T, Kunisada, T, Iwama, T (2007) Long-term maintenance of brain tumor stem cell properties under at non-adherent and adherent culture conditions. Biochem Biophys Res Commun 361: pp. 586-592 CrossRef
  2. Pollard, SM, Yoshikawa, K, Clarke, ID, Danovi, D, Stricker, S, Russell, R, Bayani, J, Head, R, Lee, M, Bernstein, M, Squire, JA, Smith, A, Dirks, P (2009) Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell 4: pp. 568-580 CrossRef
  3. Potter, NE, Phipps, K, Harkness, W, Hayward, R, Thompson, D, Jacques, TS, Harding, B, Thomas, DG, Rees, J, Darling, JL, Warr, TJ (2009) Astrocytoma derived short-term cell cultures retain molecular signatures characteristic of the tumour in situ. Exp Cell Res 315: pp. 2835-2846 CrossRef
  4. Fael Al-Mayhani, TM, Ball, SL, Zhao, JW, Fawcett, J, Ichimura, K, Collins, PV, Watts, C (2009) An efficient method for derivation and propagation of glioblastoma cell lines that conserves the molecular profile of their original tumours. J Neurosci Methods 176: pp. 192-199 CrossRef
  5. Wakimoto, H, Mohapatra, G, Kanai, R, Curry, WT, Yip, S, Nitta, M, Patel, AP, Barnard, ZR, Stemmer-Rachamimov, AO, Louis, DN, Martuza, RL, Rabkin, SD (2012) Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells. Neuro Oncol 14: pp. 132-144 CrossRef
  6. Qiu, B, Zhang, D, Tao, J, Wu, A, Wang, Y (2012) A simplified and modified procedure to culture brain glioma stem cells from clinical specimens. Oncol Lett 3: pp. 50-54
  7. Wykosky, J, Gibo, DM, Stanton, C, Debinski, W (2008) Interleukin-13 receptor alpha 2, EphA2, and Fos-related antigen 1 as molecular denominators of high-grade astrocytomas and specific targets for combinatorial therapy. Clin Cancer Res 14: pp. 199-208 CrossRef
  8. Pandya, H, Gibo, DM, Garg, S, Kridel, S, Debinski, W (2012) An interleukin 13 receptor α 2-specific peptide homes to human Glioblastoma multiforme xenografts. Neuro Oncol 14: pp. 6-18 CrossRef
  9. Mintz, A, Gibo, DM, Madhankumar, AB, Debinski, W (2003) Molecular targeting with recombinant cytotoxins of interleukin-13 receptor alpha2-expressing glioma. J Neurooncol 64: pp. 117-123
  10. Kesari, S, Bota, DA (2011) Fos-related antigen-1 (Fra-1) is a regulator of glioma cell malignant phenotype. Cancer Biol Ther 11: pp. 307-310 CrossRef
  11. Debinski, W, Gibo, DM (2005) Fos-related antigen 1 modulates malignant features of glioma cells. Mol Cancer Res 3: pp. 237-249
  12. Li, X, Wang, L, Gu, JW, Li, B, Liu, WP, Wang, YG, Zhang, X, Zhen, HN, Fei, Z (2010) Up-regulation of EphA2 and down-regulation of EphrinA1 are associated with the aggressive phenotype and poor prognosis of malignant glioma. Tumour Biol 31: pp. 477-488 CrossRef
  13. Wang, LF, Fokas, E, Bieker, M, Rose, F, Rexin, P, Zhu, Y, Pagenstecher, A, Engenhart-Cabillic, R, An, HX (2008) Increased expression of EphA2 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients. Oncol Rep 19: pp. 151-156
  14. Hatano, M, Eguchi, J, Tatsumi, T, Kuwashima, N, Dusak, JE, Kinch, MS, Pollack, IF, Hamilton, RL, Storkus, WJ, Okada, H (2005) EphA2 as a glioma-associated antigen: a novel target for glioma vaccines. Neoplasia 7: pp. 717-722 CrossRef
  15. Ohgaki, H, Kleihues, P (2011) Genetic profile of astrocytic and oligodendroglial gliomas. Brain Tumor Pathol 28: pp. 177-183 CrossRef
  16. Pojo, M, Costa, BM (2011) Molecular Hallmarks of Gliomas. Molecular Targets of CNS Tumors. InTech, ? pp. 177-200
  17. Du
• 刊物主题：Cancer Research; Cell Biology;
• 出版者：BioMed Central
• ISSN：1475-2867

文摘

Background The molecular heterogeneity of high-grade astrocytomas underlies the difficulties in the development of representative and valuable in vitro experimental models for their studies. The purpose of our study was to estimate the value of astrocytoma-associated antigens (AAAs) - IL13Rα2, Fra-1, EphA2 - and the most common molecular aberrations typical for astrocytomas as potential markers to screen the status of tumour-derived cell cultures in vitro. Methods The tumour-derived cell cultures were established from high-grade astrocytomas. The expression analyses of the tested genes were performed via semi-quantitative real-time PCR and subsequently verified by immunohistochemical and immunocytochemical technique. The analyses of molecular aberrations at DNA level included gene dosage status evaluation based on real-time PCR, sequencing analysis, and loss of heterozygosity (LOH) assay. Results The expression analyses based on semi-quantitative real-time PCR showed that in the final stage of culture the expression level of all tested AAAs was significantly higher or at least comparable to that of primary tumours; however, two expression patterns were observed during cell culture establishment. Analysis at the single cell level via immunocytochemistry also demonstrated an increase of the level of tested proteins and/or selection of tumour cell populations strongly positive for AAAs vs. other cell types including admixed non-tumoural cells. Confrontation of AAA expression data with the results of molecular analyses at DNA level seems to support the latter, revealing that the expression pattern of astrocytoma-associated antigens in tumour-derived cells in subsequent stages of culture is convergent with changes in the molecular profile of examined cell populations. Conclusions The consistency of the obtained results seems to support the use of the selected AAAs, in particular IL13Rα2 and Fra-1, as tools facilitating the establishment of tumour-derived cultures. However, the intratumoural heterogeneity of high-grade astrocytomas may require further detailed characterisation of the molecular profile of a tumour in order to evaluate the value of the experimental model in relation to the individual context of particular studies.